<?xml version="1.0"?>
<metadata xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dc="http://purl.org/dc/elements/1.1/"><dc:title>The role of PI3K/AKT and MAPK signaling pathways in erythropoietin signalization</dc:title><dc:creator>Tóthová,	Zuzana	(Avtor)
	</dc:creator><dc:creator>Šemeláková,	Martina	(Avtor)
	</dc:creator><dc:creator>Solárová,	Zuzana	(Avtor)
	</dc:creator><dc:creator>Tomc,	Jana	(Avtor)
	</dc:creator><dc:creator>Debeljak,	Nataša	(Avtor)
	</dc:creator><dc:creator>Solár,	Peter	(Avtor)
	</dc:creator><dc:subject>erythropoietin</dc:subject><dc:subject>PI3K</dc:subject><dc:subject>MAPK</dc:subject><dc:description>Erythropoietin (EPO) is a glycoprotein cytokine known for its pleiotropic effects on varioustypes of cells and tissues. EPO and its receptor EPOR trigger signaling cascades JAK2/STAT5,MAPK, and PI3K/AKT that are interconnected and irreplaceable for cell survival. In this article, wedescribe the role of the MAPK and PI3K/AKT signaling pathways during red blood cell formationas well as in non-hematopoietic tissues and tumor cells. Although the central framework of thesepathways is similar for most of cell types, there are some stage-specific, tissue, and cell-lineagedifferences. We summarize the current state of research in this field, highlight the novel members ofEPO-induced PI3K and MAPK signaling, and in this respect also the differences between erythroidand non-erythroid cells.</dc:description><dc:date>2021</dc:date><dc:date>2022-03-29 11:49:51</dc:date><dc:type>Članek v reviji</dc:type><dc:identifier>135709</dc:identifier><dc:identifier>UDK: 616.1</dc:identifier><dc:identifier>ISSN pri članku: 1422-0067</dc:identifier><dc:identifier>DOI: 10.3390/ijms22147682</dc:identifier><dc:identifier>COBISS_ID: 71385603</dc:identifier><dc:language>sl</dc:language></metadata>
